Stock Financial Ratios, Dividends, Split History

CBIS / Cannabis Science, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price0.07
Volume33,704,700.00
Market Cap ($M)179.00
Book Value ($M)-2.61
Book Value / Share-0.00
Price / Book-68.60
NCAV ($M)-3.96
NCAV / Share-0.00
Price / NCAVn/a
Share Statistics
Common Shares Outstanding2 2,466,805,296
Common Shares Outstanding 2,350,355,296
Preferred Stock Shares Outstanding 1,000,000
Common Stock Shares Outstanding 2,350,355,296
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)5.41
Return on Assets (ROA)-5.55
Return on Equity (ROE)4.75
Balance Sheet (mrq) ($M)
Assets2.08
Liabilities4.43
Quick Ratio0.06
Current Ratio0.09
Income Statement (mra) ($M)
Revenues9,263.00
Operating Income-8.52
Net Income-9.99
Earnings Per Share Basic And Diluted0.00
Cash Flow Statement (mra) ($M)
Cash From Operations-1.69
Cash from Investing-0.01
Cash from Financing-0.01
Identifiers and Descriptors
CUSIP137648101
Central Index Key (CIK)1024626

Split History

Stock splits are used by Cannabis Science, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
CBIS : Cannabis Science Stock Analysis and Research Report

2017-11-23 - Asif

Business Overview Cannabis Science, Inc. (formerly Gulf Onshore, Inc.) (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 7, 2009, the Company changed its name to Cannabis Science, Inc. Cannabis Science, Inc. is at the forefront of medical cannabis research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In summary, Cannabis Science is dedicated to the creation of cannabis-based...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Americann Partnership with C3RN Commences Cannabis Research In Massachusetts

2018-07-09 accesswire
DENVER, CO / ACCESSWIRE / July 9, 2018 / AmeriCann, Inc. (OTCQB: ACAN), an agricultural-technology company that is developing the next generation of eco-friendly state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that it is leading a research pilot study in Massachusetts. The research is led by Cannabis Community Care and Research Network (C3RN) in collaboration with UMass Dartmouth. (2-0)

Americann CEO to Present at Science and Education Conference in Massachusetts

2018-06-28 accesswire
DENVER, CO / ACCESSWIRE / June 28, 2018 / AmeriCann, Inc. (OTCQB: ACAN), an Agricultural-Technology company that is developing the next generation of eco-friendly state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that CEO Tim Keogh will be speaking at Cannabis Community Care and Research Network's (C3RN) Cannabis Science and Education Series on Thursday, June 28 in Worcester, MA. (9-0)

AmeriCann Partners with C3RN to Conduct Scientific Cannabis Research in Massachusetts

2018-06-20 accesswire
DENVER, CO / ACCESSWIRE / June 20, 2018 / AmeriCann, Inc. (OTCQB: ACAN), an Agricultural-Technology company that is developing the next generation of eco-friendly state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that it is formally partnering with Cannabis Community Care and Research Network (C3RN), a Massachusetts-based public benefit corporation focused on cannabis research and technology. (9-0)

30 Marijuana Stocks to Buy as the Future Turns Green

2018-05-14 investorplace
When it comes to cannabis, we’ve come a long way since former President Bill Clinton denied ever inhaling. With the previous presidential administration’s frankness on the matter, marijuana has become more blasé. Naturally, marijuana stocks have also increased in popularity, where we have more choices today than was previously thought possible. (149-27)

CUSIP: 137648101